Loading...
•
Jun 30, 2023
PTC Therapeutics Q2 2023 Earnings Report
PTC Therapeutics' second quarter results for 2023 were announced, featuring a 29% year-over-year revenue growth and advancements in clinical trials and regulatory milestones.
Key Takeaways
PTC Therapeutics reported a 29% year-over-year revenue growth in the second quarter of 2023, with total revenue reaching $213.8 million. The company saw positive data readouts from APHENITY and PIVOT-HD trials and anticipates several regulatory submissions in the second half of the year.
Total revenue for Q2 2023 reached $213.8 million, a 29% increase year-over-year.
DMD franchise revenue was $162 million, representing a 21% year-over-year growth.
Translarna revenue was $96 million, driven by new patients and geographic expansion.
Emflaza revenue was $66 million, driven by new patients and high compliance.
Revenue by Segment
Forward Guidance
PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion. PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 and $575 million.
Positive Outlook
- Total revenues for the full year 2023 to be between $940 million and $1.0 billion.
- Net product revenues for the DMD franchise for the full year 2023 to be between $545 and $575 million.
- GAAP R&D and SG&A expense for the full year 2023 to be between $930 million and $980 million.
- Non-GAAP R&D and SG&A expense for the full year to be between $810 million and $860 million, excluding estimated non-cash stock-based compensation expense of $120 million.
- Up to $62 million of one-time expenses, paid in cash or equity ($37 million of which was incurred during the first half of 2023), upon achievement of potential clinical and regulatory success-based milestones from previous acquisitions and expenses associated with a rights exchange agreement.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...